No content results match your keyword.
Content
You have successfully logged out.
Not registered yet?
No content results match your keyword.
Content
No product results match your keyword.
Products
SeQuent® DCBs
Enter the world of SeQuent® DCB treatment with cutting-edge balloon technology and a proven leader at your side – for more drug options, more clinical data, high-quality support and the confidence you’re aiming for.
Cooperation
At the recent DCB Days nine esteemed DCB experts like Raban Jeger and Robert Byrne shared their key concepts and insights on the principle of leaving nothing behind in coronary vessels. The course covered key concepts and practical applications, allowing attendees to deepen their understanding and enhance their skills in this area.
Read articlePaclitaxel coated balloon
SeQuent® Please NEO
> 0
published studies
> 0
documented patients
> 0
countries
Sirolimus coated balloon
B. Braun´s new sirolimus coated balloon is the first SCB backed up with published randomized clinical trials for ISR and de-novo lesions. [2], [3], [4] SeQuent® SCB now offers new implant-free options for treating coronary ISR and de-novo lesions, providing excellent results in targeted drug delivery and sirolimus persistence. The combination of sirolimus and BHT (Butylated Hydroxy Toluol) creates the desired crystalline sirolimus modification to reach best results regarding sirolimus vessel wall content compared to other excipients. [5]
2020 | Primary Investigator: Jeger R | Study Aim: SQP vs. DES, Vessel: RD ≤ 3 mm | (Primary) Endpoint: MACE @ 36-month follow-up | Patients: 758
Summary BASKET-SMALL 22017 | Primary Investigator: Funatsu A | Study Aim: DCB vs. POBA, Vessel: RD ≤ 2.75 mm, ≥ 2 mm | (Primary) Endpoint: TVF @ 6-month follow-up | Patients: 135
Summary PEPCAD Japan SVD2017 | Primary Investigator: Gobić D | Study Aim: DCB vs. DES, Patients: STEMI (< 12 h) | (Primary) Endpoint: MACE, LLL @ 6-month follow-up | Patients: 75
Summary AMI Feasibility Study2016 | Primary Investigator: Nishiyama N | Study Aim: DCB vs. DES | (Primary) Endpoint: TLR @ 8-month follow-up | Patients: 60
Summary Clinical Value "Stent-less" PCI2019 | Primary Investigator: Rosenberg M | Study Aim: DCB – ISR & De Novo | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 1,025
Summary DCB-only All-Comers Registry2016 | Primary Investigator: Shin E | Study Aim: DCB – De Novo, Vessel: RD ≤ 3.5 mm, ≥ 2.5 mm | (Primary) Endpoint: LLL, FFR @ 9-month follow-up, MI, TLR @ 12-month follow-up | Patients: 67
Summary FFR-Guided DCB-Angioplasty2014 | Primary Investigator: Zeymer U | Study Aim: DCB – De Novo, Vessel: RD ≤ 2.75 mm, ≥ 2.0 mm | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 447
Summary SVD Registry2023 | Primary Investigator: Shin ES | Study Aim: Investigate the impact of DCB-based treatment on PCI for multivessel CAD | (Primary) Endpoint: MACE @ 24-months (cardiac death, MI, TVR, stroke, stent thrombosis and major bleeding) | Patients: 508
Summary DCB-based PCI in Multi-Vessel-DiseaseSirolimus + BHT (Butylated Hydroxy Toluol): Persistence in the vessel wall
Read moreTwo RCTs for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.
Read summaryRCT for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.
Read summarySeQuent® Please NEO
Clinically proven drug coated balloon catheter
link
SeQuent® SCB
Sirolimus coated balloon catheter for PTCA
link
SeQuent® Please NEO – Go Implant-Free!
Safe and effective alternative to DES in de novo lesions
pdf, 27.8 KB
Cardiology Catalog
Your partner for coronary angioplasty
link
Your feedback matters! Participate in our customer survey to help us enhance our website, products and services. Thank you for your support!
